Imiquimod for treatment of vulvar and vaginal intraepithelial neoplasia.
We searched PubMed, Scopus, Web of Science, LILACS, EMBASE, and Cochrane Library databases to assess the effectiveness and safety of 5% imiquimod cream in the treatment of vulvar and vaginal intraepithelial neoplasia. From the results of the 17 relevant articles identified (1 reported on a randomized controlled trial, 10 reported on case series, and 6 were case reports), 26% to 100% of patients had complete regression, 0% to 60% had partial regression, and 0% to 37% experienced recurrence. The most common adverse events were local burning and soreness, but not severe enough for patients to discontinue treatment. From these reports imiquimod treatment leads to complete response in a considerable percentage of patients, and those who experience partial response will require less extensive excision. Treating vulvar and vaginal intraepithelial neoplasia with 5% imiquimod cream therefore appears to be promising.
Iavazzo
Christos
C
Alfa Institute of Biomedical Sciences (AIBS), Athens, Greece.
Pitsouni
Eleni
E
Athanasiou
Stavros
S
Falagas
Matthew E
ME
D000279:Administration, Cutaneous; D000282:Administration, Intravaginal; D000634:Aminoquinolines / Q000008:administration & dosage*; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D002278:Carcinoma in Situ / Q000188:drug therapy*; D005260:Female; D006801:Humans; D000077271:Imiquimod; D011230:Precancerous Conditions / Q000188:drug therapy*; D016896:Treatment Outcome; D014625:Vaginal Neoplasms / Q000188:drug therapy*; D014846:Vulvar Neoplasms / Q000188:drug therapy*
D000634:Aminoquinolines; D000970:Antineoplastic Agents; D000077271:Imiquimod